ADC Therapeutics (ADCT) Equity Average (2022 - 2026)

ADC Therapeutics has disclosed Equity Average across 5 years of filings, most recently posting -$201.1 million for Q1 2026.

• Equity Average for Q1 2026 came in at -$201.1 million, up 8.77% year-over-year; the trailing twelve-month figure through Mar 2026 was -$201.1 million (up 8.77% YoY), and the FY2025 annual result was -$194.2 million, down 10.71% from the prior year.
• Equity Average came in at -$201.1 million for Q1 2026 at ADC Therapeutics, up from -$212.0 million in the prior quarter.
• In the past five years, Equity Average ranged from a high of $116.7 million in Q4 2022 to a low of -$220.4 million in Q1 2025.
• The 5-year median for Equity Average is -$167.2 million (2024), against an average of -$122.7 million.
• Across the five-year window, Equity Average plunged 3837.33% in 2024 and increased 8.77% in 2026, its largest moves.
• ADC Therapeutics' Equity Average stood at $116.7 million in 2022, then sank by 191.01% to -$106.2 million in 2023, then tumbled by 76.28% to -$187.3 million in 2024, then slipped by 13.2% to -$212.0 million in 2025, then climbed by 5.14% to -$201.1 million in 2026.
• The last three Equity Average figures came in at -$201.1 million (Q1 2026), -$212.0 million (Q4 2025), and -$218.7 million (Q3 2025), per Business Quant data.